38 research outputs found
Endovascular treatment of visceral artery pseudoaneurysms with ethylene-vinyl alcohol (evoh) copolymer-based non-adhesive liquid embolic agents (naleas)
Background and Objectives: Treatment of visceral artery pseudoaneurysms (VAPs) is always
indicated regardless of their diameters, as their risk of rupture is significantly higher than that of
visceral artery aneurysms. The invasiveness of surgery and its associated complications have led
to a shift in favor of radiological interventions as the initial treatment of choice. However, there
are still some unanswered questions on endovascular treatment of VAPs regarding the optimal
endovascular technique and the efficacy and safety outcomes. The purpose of this multicenter
study was to retrospectively evaluate the effectiveness and safety of endovascular treatment of
visceral pseudoaneurysms using Ethylene-Vinyl Alcohol (EVOH) Copolymer-Based Non-Adhesive
Liquid Embolic Agents (NALEAs). Materials and Methods: Consecutive patients who underwent
endovascular embolization with EVOH-based NALEAs for visceral artery pseudoaneurysms between
January 2018 and June 2023 were retrospectively evaluated. Results: 38 embolizations were performed.
Technical success was achieved in all patients. The clinical success rate was high (92.1% overall),
with no significant differences between ruptured and unruptured VAPs (p = 0.679). Seven patients
(18.4%) experienced procedure-related complications, related to one case of non-target embolization,
four splenic abscesses due to end-organ infarction, and two femoral pseudoaneurysms. The rates of
procedure-related complications, end-organ infarction, and vascular access-site complications did
not significantly differ between ruptured and unruptured VAPs (p > 0.05). Conclusions: Both ruptured
and unruptured visceral pseudoaneurysms can be effectively and safely treated with NALEA-based
endovascular embolization. We suggest considering the use of NALEAs, particularly in specific
clinical cases that highlight their advantages, including patients with coagulopathy, fragile vessels,
and embolization targets that are located at a considerable distance from the microcatheter tip and
are otherwise difficult to reach
COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context
Background and objectives: It is unclear how multiple sclerosis (MS) affects the severity of COVID-19. The aim of this study is to compare COVID-19-related outcomes collected in an Italian cohort of patients with MS with the outcomes expected in the age- and sex-matched Italian population. Methods: Hospitalization, intensive care unit (ICU) admission, and death after COVID-19 diagnosis of 1,362 patients with MS were compared with the age- and sex-matched Italian population in a retrospective observational case-cohort study with population-based control. The observed vs the expected events were compared in the whole MS cohort and in different subgroups (higher risk: Expanded Disability Status Scale [EDSS] score > 3 or at least 1 comorbidity, lower risk: EDSS score ≤ 3 and no comorbidities) by the χ2 test, and the risk excess was quantified by risk ratios (RRs). Results: The risk of severe events was about twice the risk in the age- and sex-matched Italian population: RR = 2.12 for hospitalization (p < 0.001), RR = 2.19 for ICU admission (p < 0.001), and RR = 2.43 for death (p < 0.001). The excess of risk was confined to the higher-risk group (n = 553). In lower-risk patients (n = 809), the rate of events was close to that of the Italian age- and sex-matched population (RR = 1.12 for hospitalization, RR = 1.52 for ICU admission, and RR = 1.19 for death). In the lower-risk group, an increased hospitalization risk was detected in patients on anti-CD20 (RR = 3.03, p = 0.005), whereas a decrease was detected in patients on interferon (0 observed vs 4 expected events, p = 0.04). Discussion: Overall, the MS cohort had a risk of severe events that is twice the risk than the age- and sex-matched Italian population. This excess of risk is mainly explained by the EDSS score and comorbidities, whereas a residual increase of hospitalization risk was observed in patients on anti-CD20 therapies and a decrease in people on interferon
DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France
We evaluated the effect of DMTs on Covid-19 severity in patients with MS, with a pooled-analysis of two large cohorts from Italy and France. The association of baseline characteristics and DMTs with Covid-19 severity was assessed by multivariate ordinal-logistic models and pooled by a fixed-effect meta-analysis. 1066 patients with MS from Italy and 721 from France were included. In the multivariate model, anti-CD20 therapies were significantly associated (OR = 2.05, 95%CI = 1.39–3.02, p < 0.001) with Covid-19 severity, whereas interferon indicated a decreased risk (OR = 0.42, 95%CI = 0.18–0.99, p = 0.047). This pooled-analysis confirms an increased risk of severe Covid-19 in patients on anti-CD20 therapies and supports the protective role of interferon
MtDNA-maintenance defects: syndromes and genes
A large group of mitochondrial disorders, ranging from early-onset pediatric encephalopathic syndromes to late-onset myopathy with chronic progressive external ophthalmoplegia (CPEOs), are inherited as Mendelian disorders characterized by disturbed mitochondrial DNA (mtDNA) maintenance. These errors of nuclear-mitochondrial intergenomic signaling may lead to mtDNA depletion, accumulation of mtDNA multiple deletions, or both, in critical tissues. The genes involved encode proteins belonging to at least three pathways: mtDNA replication and maintenance, nucleotide supply and balance, and mitochondrial dynamics and quality control. In most cases, allelic mutations in these genes may lead to profoundly different phenotypes associated with either mtDNA depletion or multiple deletions.
Communicated by: Shamima Rahman
Presented at the Annual Symposium of the Society for the Study of Inborn Errors of Metabolism, Rome, Italy, September 6–9, 2016This work was supported by: ERC FP7-322424 grant (to MZ), CoEN grant 3038 (to MZ and CV) and the MRC core grant to the Mitochondrial Biology Unit